Product
OC-DC
1 clinical trial
1 indication
Indication
Ovarian CancerClinical trial
Phase I/II Study to Test the Immunogenicity, Feasibility, and Safety of Autologous PEP-DC Vaccine vs. Autologous OC-DC Vaccine Followed by PEP-DC Vaccine, in Combination With Low-dose Cyclophosphamide, in Patients With Advanced HGSOCStatus: Not yet recruiting, Estimated PCD: 2030-03-01